This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Giardina, E. G. Articles by Kantor, S. J. Search for Related Content PubMed PubMed Citation Articles by Giardina, E. G. Articles by Kantor, S. J.

Circulation, Vol 60, 1045-1052, Copyright © 1979 by American Heart Association

ARTICLES

The electrocardiographic and antiarrhythmic effects of imipramine hydrochloride at therapeutic plasma concentrations

EG Giardina, JT Bigger Jr, AH Glassman, JM Perel and SJ Kantor

The electrocardiographic effects of imipramine hydrochloride at therapeutic plasma concentrations were determined in 44 depressed patients during a 6-week clinical outcome study of depression. During each week of the protocol, i.e., 2 weeks of control and 4 weeks of drug treatment, a standard 12-lead ECG, high-speed, high-fidelity ECG tracings, and a 24-hour continuous ECG recording were obtained. PR, QRS, and QTc intervals, T-wave amplitude, heart rate and frequency of ventricular premature depolarizations (VPDs) were measured. The plasma concentration of imipramine and desmethylimipramine was measured three times a week. Imipramine prolonged the PR (p less than 0.001), QRS (p less than 0.001) and QTc (p less than 0.001) intervals, increased the heart rate (p less than 0.001) and lowered T-wave amplitude (p less than 0.05) during the 4 weeks of treatment. No patient developed high- grade atrioventricular block or severe intraventricular conduction abnormalities. In addition, imipramine had a potent antiarrhythmic action in patients who were recovering from depression. Ten of 11 patients who had more than 10 VPDs/hour had 90% or greater arrhythmia suppression during antidepressant treatment with imipramine at plasma concentrations ranging from 100--302 ng/ml.

This article has been cited by other articles:

				D. L Nykamp, C. L Blackmon, P. E Schmidt, and A. G Roberson QTc Prolongation Associated with Combination Therapy of Levofloxacin, Imipramine, and Fluoxetine Ann. Pharmacother., March 1, 2005; 39(3): 543 - 546. [Abstract] [Full Text] [PDF]

				J. W. Mason and The Electrophysiologic Study versus Electrocardiog A Comparison of Seven Antiarrhythmic Drugs in Patients with Ventricular Tachyarrhythmias N. Engl. J. Med., August 12, 1993; 329(7): 452 - 458. [Abstract] [Full Text]

				A. H. Glassman, S. P. Roose, and J. T. Bigger Jr The Safety of Tricyclic Antidepressants in Cardiac Patients: Risk-Benefit Reconsidered JAMA, May 26, 1993; 269(20): 2673 - 2675. [Abstract] [PDF]

				S. P. Roose, A. H. Glassman, E. G. V. Giardina, B. T. Walsh, S. Woodring, and J. T. Bigger Tricyclic Antidepressants in Depressed Patients With Cardiac Conduction Disease Arch Gen Psychiatry, March 1, 1987; 44(3): 273 - 275. [Abstract] [PDF]

				D. A. Frommer, K. W. Kulig, J. A. Marx, and B. Rumack Tricyclic Antidepressant Overdose: A Review JAMA, January 23, 1987; 257(4): 521 - 526. [Abstract] [PDF]

				W. G. Iacono, D. T. Lykken, L. J. Peloquin, A. E. Lumry, R. H. Valentine, and V. B. Tuason Electrodermal Activity in Euthymic Unipolar and Bipolar Affective Disorders: A Possible Marker for Depression Arch Gen Psychiatry, May 1, 1983; 40(5): 557 - 565. [Abstract] [PDF]

				A. H. Glassman and J. T. Bigger Jr Cardiovascular Effects of Therapeutic Doses of Tricyclic Antidepressants: A Review Arch Gen Psychiatry, July 1, 1981; 38(7): 815 - 820. [Abstract] [PDF]